portfolio
ArriVent Expands ADC Portfolio with $615 Million Alphamab Acquisition
ArriVent, ADC portfolio, Alphamab, acquisition, biotech, biotechnology, financing
Lilly Expands Radiopharmaceutical Portfolio with Aktis Acquisition
Lilly, Aktis, radiopharmaceutical, acquisition, portfolio, cancer therapy, targeted treatment
Roche Streamlines Portfolio, Prioritizes High-Impact Projects After Pipeline Reduction
Roche, pharmaceuticals, pipeline, portfolio optimization, high-impact projects, strategic decision, drug development
Incyte Expands Portfolio with $750 Million Acquisition of Escient, a Pioneer in Immune and Neuro Biotechnology
Incyte, Escient, biotechnology, immune system, neuroscience, acquisition, deal, $750 million, portfolio expansion, drug development, therapeutics, GPCR targets.
AbbVie Emerges as Leading Immunology Company in Doctor Rankings, Surpassing Pfizer and Johnson & Johnson
AbbVie, Pfizer, Johnson & Johnson, doctor ranking, immunology companies, pharmaceutical industry, market performance, reputation, product portfolio.
Boehringer Ingelheim and Sosei Sign Potential $732 Million Collaboration for Schizophrenia Treatment
Boehringer Ingelheim, Sosei, Schizophrenia Treatment, Partnership, $732 Million Deal, GPR52 Targeting Portfolio